Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
|
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [1] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
    Giorgi Nadiradze
    Urs Giger-Pabst
    Juergen Zieren
    Dirk Strumberg
    Wiebke Solass
    Marc-André Reymond
    Journal of Gastrointestinal Surgery, 2016, 20 : 367 - 373
  • [2] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
    Nadiradze, Giorgi
    Giger-Pabst, Urs
    Zieren, Juergen
    Strumberg, Dirk
    Solass, Wiebke
    Reymond, Marc-Andre
    JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 20 (02) : 367 - 373
  • [3] Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Erik, Brecelj
    Katja, Kopriva Pirtovsek
    Jani, Izlakar
    Nina, Boc
    ONKOLOGIJA, 2019, 23 (02) : 38 - 41
  • [4] Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis (PIPAC-GA1).
    Struller, Florian
    Horvath, Philipp
    Solass, Wiebke
    Weinreich, Frank Jurgen
    Konigsrainer, Alfred
    Reymond, Marc A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treatment of advanced ovarian cancer. A review of the literature
    Psomiadou, Victoria
    Fotiou, Alexandros
    Prodromidou, Anastasia
    Iavazzo, Christos
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (01) : 73 - 77
  • [6] Pressurized intraperitoneal aerosol chemotherapy (PIPAC): A new way of administration in peritoneal carcinomatosis of ovarian cancer
    Sabaila, A.
    Fauconnier, A.
    Huchon, C.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2015, 43 (01): : 66 - 67
  • [7] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review
    Taliento, Cristina
    Restaino, Stefano
    Scutiero, Gennaro
    Arcieri, Martina
    Bernardi, Giulia
    Martinello, Ruby
    Driul, Lorenza
    Perrone, Anna Myriam
    Fagotti, Anna
    Scambia, Giovanni
    Greco, Pantaleo
    Vizzielli, Giuseppe
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A407 - A407
  • [8] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review
    Taliento, Cristina
    Restaino, Stefano
    Scutiero, Gennaro
    Arcieri, Martina
    Bernardi, Giulia
    Martinello, Ruby
    Driul, Lorenza
    Perrone, Anna Myriam
    Fagotti, Anna
    Scambia, Giovanni
    Greco, Pantaleo
    Vizzielli, Giuseppe
    EJSO, 2023, 49 (12):
  • [9] Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Why it will transform cancer surgery
    Reymond, Marc Andre
    Sautkin, Yaroslv
    Schoenfelder, Hans
    Solass, Wiebke
    FORMOSAN JOURNAL OF SURGERY, 2024, 57 (06) : 225 - 231
  • [10] Hospitalization cost of Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC)
    Tidadini, Fatah
    Trilling, Bertrand
    Aime, Adeline
    Abba, Julio
    Quesada, Jean-Louis
    Foote, Alison
    Chevallier, Thierry
    Glehen, Olivier
    Faucheron, Jean -Luc
    Chkair, Sihame
    Arvieux, Catherine
    EJSO, 2023, 49 (01): : 165 - 172